Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Small, but heading for the big time: Nanobiotix revenue for the 1st quarter of 2014 and new composition of the shareholding

Abstract:
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenue for the first quarter of 2014 and presents the new breakdown of its share capital pursuant to the capital increase with preferential subscription rights completed in March 2014.

Small, but heading for the big time: Nanobiotix revenue for the 1st quarter of 2014 and new composition of the shareholding

Paris, France | Posted on May 12th, 2014

Activity

The revenue recorded by NANOBIOTIX during the first quarter of 2014 corresponds to the upfront payment (pro-rata share) received by the company from Taiwan-based PharmaEngine, within the framework of the licensing contract. This licensing contract was signed with PharmaEngine in August 2012 for the development and commercialization of the lead product, NBTXR3 in the Asia-Pacific region. The total upfront payment totaled €810,640 and is apportioned using the straight-line method across the period between the date the contract was signed and the scheduled marketing launch in the region which is anticipated as 2017.

During the quarter, the most significant event has been a capital increase with preferential subscription rights. The subscription ratio was 3 new shares for 14 existing shares at a subscription price of €10.60 per share. The capital increase was successfully completed on 20 March 2014 and the total amount raised was €28.1 million, after full exercise of the extension clause. The settlement-delivery and the trading of the new shares occurred on 24 March 2014. The rationale for raising these funds was mainly to support the acceleration of the product pipeline.

The company believes that the coming year is going to be a pivotal one for its development, in particular with respect to operational and clinical progress.

New composition of Nanobiotix shareholding structure following the capital increase which took place in March 2014

Following the completion of the capital increase, the original institutional shareholders remaining invested in the company represent 30.2% of its capital. A great number of new shareholders have acquired shares, with a significant increase of retail shareholders (43.6% of the capital against 13.1% previously), and with the arrival of a large number of foreign (non-French) institutional investors (79 shareholders representing 10.7% of the capital compared to 2% previously) mainly from Belgium, the Netherlands, Luxemburg and Italy.

Although the capital increase has resulted in an increase in the number of French institutional investors (from 4 to 30), their aggregate proportion decreased from 15% to 8.2%.

In total, institutional investors represent 49.1% of the capital.

Next financial press release: revenue for the second quarter of 2014, on July 11, 2014

####

About Nanobiotix
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration.

Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

Issued for and on behalf of Nanobiotix by Instinctif Partners.

For more information, please click here

Contacts:
Nanobiotix
Sarah Gaubert
Head of Communication and Public Affairs
+33 (0)1 40 26 07 55



NewCap.
Financial communication and investors relations
Louis-Victor Delouvrier / Emmanuel Huynh
+33 (0)1 44 71 98 53



Yucatan
Media relations (France)
Annie-Florence Loyer/ Nadège Le Lezec
+33 (0)6 88 20 35 59
/


Instinctif Partners
Media relations (Outside France)
Melanie Toyne Sewell / Katherine Lynch
+44 (0) 207 457 2020

Copyright © Nanobiotix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

UK NANOSAFETY GROUP publishes 2nd Edition of guidance to support safe working with nanomaterials May 30th, 2016

Fast, stretchy circuits could yield new wave of wearable electronics May 30th, 2016

Automating DNA origami opens door to many new uses: Like 3-D printing did for larger objects, method makes it easy to build nanoparticles out of DNA May 30th, 2016

Simple attraction: Researchers control protein release from nanoparticles without encapsulation: U of T Engineering discovery stands to improve reliability and fabrication process for treatments to conditions such as spinal cord damage and stroke May 28th, 2016

Nanomedicine

Automating DNA origami opens door to many new uses: Like 3-D printing did for larger objects, method makes it easy to build nanoparticles out of DNA May 30th, 2016

Simple attraction: Researchers control protein release from nanoparticles without encapsulation: U of T Engineering discovery stands to improve reliability and fabrication process for treatments to conditions such as spinal cord damage and stroke May 28th, 2016

Scientists illuminate a hidden regulator in gene transcription: New super-resolution technique visualizes important role of short-lived enzyme clusters May 27th, 2016

Supercrystals with new architecture can enhance drug synthesis May 24th, 2016

Announcements

UK NANOSAFETY GROUP publishes 2nd Edition of guidance to support safe working with nanomaterials May 30th, 2016

Fast, stretchy circuits could yield new wave of wearable electronics May 30th, 2016

Automating DNA origami opens door to many new uses: Like 3-D printing did for larger objects, method makes it easy to build nanoparticles out of DNA May 30th, 2016

Simple attraction: Researchers control protein release from nanoparticles without encapsulation: U of T Engineering discovery stands to improve reliability and fabrication process for treatments to conditions such as spinal cord damage and stroke May 28th, 2016

Financial Reports

Nanometrics to Announce First Quarter Financial Results on April 26, 2016 April 5th, 2016

Nanometrics Achieves Record 3D-NAND Bookings Quarter: A Record 3D-NAND Bookings Quarter, both in Aggregate and for Each of Three Key Customers March 28th, 2016

Arrowhead to Webcast Fiscal 2015 Year End Results December 7th, 2015

Haydale Announce Year End Results November 3rd, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic